Friday Mar 7
Threshold Pharmaceuticals, Inc. Reports Fourth Quarter And Year End...
Threshold Pharmaceuticals, Inc. , today reported financial results for the fourth quarter and year ended December 31, 2013 and reported on clinical development objectives for TH-302, the Company's investigational hypoxia-targeted drug, which is currently being evaluated in two pivotal Phase 3 clinical trials, one in patients with advanced soft ... (more)
Threshold Pharmaceuticals (THLD) Posts Quarterly Earnings, Misses Expectations By $0.03 EPS
Threshold Pharmaceuticals announced its earnings results on Thursday. The company reported EPS for the quarter, missing the Thomson Reuters consensus estimate of by $0.03, American Banking News reports.
Threshold Pharmaceuticals Inc - 10-K - Management's Discussion and...
The following discussion and analysis should be read in conjunction with our consolidated financial statements and related notes included elsewhere in this Annual Report on Form 10-K.
Threshold Pharmaceuticals Announces Presentations and Webcasts at...
Threshold Pharmaceuticals, Inc. today announced that Barry Selick, Ph.D., Threshold's Chief Executive Officer, will present a company overview at three upcoming investor conferences: 2014 RBC Capital Markets' Global Healthcare Conference, Wednesday, February 26, 2014, New York, NY, at 11:30 a.m. ET; Cowen and Company 34th Annual Health Care ... (more)
Just Released: "Threshold Pharmaceuticals, Inc. (THLD) -...
The company discovers and develops therapeutics for the treatment of cancer. Its products include TH-302, TH-CR-406, MAESTRO, TH-CR-407, TH-CR-408, TH-CR-410, NCT01403610, NCT01485042, NCT01497444 and NCT01721941.